Danish biotechnology company IO Biotech has finished enrolling subjects in a Phase II trial of its lead therapeutic cancer ...

BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces ...

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV)BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Dat ...

BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response with no notable adverse events ...

The latest announcement is out from Argent Biopharma ( (AU:RGT) ).

PERTH, Australia, Jan. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments ...

Efzofitimod is under clinical development by aTyr Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Nonlinearity of the interactions is key for the speed, robustness, and flexibility of multi-agent decision-making. In this work we introduce modulatory, that is, multiplicative, in contrast to ...

The team, which also included Ph.D. students Subhasree Sridhar and Konrad Snioch and several members of the BINGs team, demonstrated that lurbinectedin's immune-modulatory effects can ...

ATL1102 was intended to inhibit the VLA-4 protein, also known as CD49d, thus “exerting an immune-modulatory effect which may be therapeutic in a range of inflammatory diseases”. But the trial failed ...

Percheron’s candidate ATL-1102 “exerts an immune-modulatory effect which may be therapeutic in a range of inflammatory diseases”. That is the hope, anyway. Yesterday, PYC said pre-clinical animal ...